RPRX

57.63

1.25% -0.73

Pre-mercato: 57.66 0.03 +0.05%

Royalty Pharma Plc (RPRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Precedente Chiudi:

$58.36

Aprire:

$58.36

Volume 24 ore:

3.24M

Relative Volume:

1.12

Capitalizzazione di mercato:

$25.66B

Reddito:

$2.44B

Utile/perdita netta:

$1.36B

Rapporto P/E:

30.18

EPS:

1.9093

Flusso di cassa netto:

$574.14M

1 W Prestazione:

-1.13%

1M Prestazione:

-7.53%

6M Prestazione:

+18.85%

1 anno Prestazione:

+58.67%

Intervallo 1D:

$57.22

$58.40

Intervallo di 1 settimana:

$57.22

$58.77

Portata 52W:

$35.23

$64.38

Royalty Pharma Plc Stock (RPRX) Company Profile

Nome

Royalty Pharma Plc

Settore

Healthcare (1068)

Industria

Biotechnology (594)

Telefono

(212) 883-0200

Indirizzo

110 EAST 59TH STREET, NEW YORK, NY

Dipendente

100

Cinguettio

Prossima data di guadagno

2026-11-04

Ultimi documenti SEC

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, MRNA, ARGX, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RPRX Royalty Pharma Plc	57.63	25.92B	2.44B	1.36B	574.14M	1.9093
VRTX Vertex Pharmaceuticals Inc	506.74	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	734.81	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	188.94	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	936.00	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.89	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-30	Aggiornamento	UBS	Neutral → Buy
2025-09-30	Iniziato	Goldman	Buy
2025-05-16	Iniziato	Morgan Stanley	Overweight
2024-06-03	Downgrade	UBS	Buy → Neutral
2022-06-14	Ripresa	UBS	Buy
2022-05-13	Iniziato	Scotiabank	Sector Outperform
2022-04-27	Iniziato	Goldman	Buy
2022-04-14	Aggiornamento	JP Morgan	Neutral → Overweight
2022-04-06	Ripresa	Morgan Stanley	Overweight
2021-10-29	Aggiornamento	Citigroup	Neutral → Buy
2021-07-30	Iniziato	Tigress Financial	Buy
2020-11-09	Aggiornamento	UBS	Neutral → Buy
2020-07-14	Iniziato	Evercore ISI	In-line
2020-07-13	Iniziato	BofA Securities	Buy
2020-07-13	Iniziato	Citigroup	Neutral
2020-07-13	Iniziato	Cowen	Outperform
2020-07-13	Iniziato	Goldman	Neutral
2020-07-13	Iniziato	JP Morgan	Neutral
2020-07-13	Iniziato	Morgan Stanley	Equal-Weight
2020-07-13	Iniziato	SunTrust	Buy
2020-07-13	Iniziato	UBS	Neutral

Mostra tutto

Royalty Pharma Plc Borsa (RPRX) Ultime notizie

Oct 01, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - theglobeandmail.com

Oct 01, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool

Oct 01, 2026

Form 4 Royalty Pharma Plc For: 1 October - Investing.com India

Oct 01, 2026

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com

Sep 30, 2026

Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 4,126 Shares of Stock - MarketBeat

Sep 30, 2026

A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan

Sep 30, 2026

4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan

Sep 30, 2026

Sep 29, 2026

If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga

Sep 29, 2026

Operating cash flow per share of Royalty Pharma Plc Class A – HAN:RPD - TradingView

Sep 29, 2026

RPD Forecast — Price Target — Prediction for 2027 - TradingView

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026

RPHC5824522 Bond Profile: Coupon and Redemption - TradingView

Sep 29, 2026

Sep 28, 2026

Royalty Pharma officer proposes $239K share sale | RPRX SEC FilingForm 144 - Stock Titan

Sep 28, 2026

Sep 27, 2026

Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Australia

Sep 27, 2026

Sep 26, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Eastern Progress

Sep 26, 2026

Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Buy at Wall Street Zen - MarketBeat

Sep 26, 2026

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com

Sep 25, 2026